Phase I and pharmacokinetic study of low-dose, three-times daily oral etoposide in patients with refractory solid tumors

被引：0
|
作者：
Schwartsmann, G
Di Leone, L
Caldas, APF
Campos, O
Cancela, AI
Viegas, MAV
Mans, DRA
机构：
[1] UFRGS, HCPA, S Amer Off Anticanc Drug Dev SOAD, Porto Alegre, RS, Brazil
[2] ULBRA, Lutheran Hosp, Porto Alegre, RS, Brazil
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
660
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [41] A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors
    Lima, CMSR
    Catapano, CV
    Pacheco, D
    Sherman, CA
    Oakhill, G
    Mushtaq, C
    Freeman, KD
    Green, MR
    CANCER, 2004, 100 (12) : 2671 - 2679
  • [42] Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
    Simonelli, Matteo
    Zucali, Paolo A.
    Lorenzi, Elena
    Rubino, Luca
    De Vincenzo, Fabio
    De Sanctis, Rita
    Perrino, Matteo
    Mancini, Luca
    Di Tommaso, Luca
    Rimassa, Lorenza
    Masci, Giovanna
    Zuradelli, Monica
    Suter, Matteo B.
    Bertossi, Monica
    Fattuzzo, Giuseppe
    Giordano, Laura
    Roncalli, Massimo G.
    Santoro, Armando
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (05) : 989 - 998
  • [43] Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors
    Fakih, MG
    Creaven, PJ
    Ramnath, N
    Trump, D
    Javle, M
    Strychor, S
    Repinski, TV
    Zamboni, BA
    Schwarz, JK
    French, RA
    Zamboni, WC
    CLINICAL CANCER RESEARCH, 2005, 11 (16) : 5942 - 5949
  • [44] A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors
    Dees, EC
    Baker, SD
    O'Reilly, S
    Rudek, MA
    Davidson, SB
    Aylesworth, C
    Elza-Brown, K
    Carducci, MA
    Donehower, RC
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 664 - 671
  • [45] Prolonged low-dose oral etoposide in children with relapsed and refractory brain tumours
    Yanagisawa, T
    Akiyama, N
    Yokoi, K
    Yuza, Y
    Katoh, Y
    Fujisawa, K
    Hoshi, Y
    Johki, T
    Takahashi, T
    Nakasaki, H
    Ohi, S
    Abe, T
    Fujisawa, J
    Etoh, Y
    NEURO-ONCOLOGY, 2004, 6 (04) : 469 - 469
  • [46] Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes
    Doll, DC
    Kasper, LM
    Taetle, R
    List, AF
    LEUKEMIA RESEARCH, 1998, 22 (01) : 7 - 12
  • [47] Phase I safety and pharmacokinetic study of oral TAS-102 once daily for fourteen days in patients with solid tumors.
    Hoff, PM
    Bogaard, K
    Lassere, Y
    Aguayo, A
    Hayakawa, T
    Abbruzzese, JL
    CLINICAL CANCER RESEARCH, 2000, 6 : 4552S - 4553S
  • [48] Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
    Eskens, FALM
    Awada, A
    Cutler, DL
    de Jonge, MJA
    Luyten, GPM
    Faber, MN
    Statkevich, P
    Sparreboom, A
    Verweij, J
    Hanauske, AR
    Piccart, M
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 1167 - 1175
  • [49] Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors
    Schwartzberg, L. S.
    Stewart, C. F.
    Schaiquevich, P.
    Legenne, P.
    Bhatt, K.
    Johns, A.
    Walker, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Development of Phase I Clinical Study of Oral Olaparib in Pediatric Patients with Refractory Solid Tumors
    Takagi, Masatoshi
    Takita, Junko
    Ogawa, Chitose
    Iehara, Tomoko
    Hosoi, Hajime
    PEDIATRIC BLOOD & CANCER, 2020, 67
12345